Avidity Biosciences, Inc. (RNA)
- Previous Close
26.06 - Open
26.30 - Bid 27.04 x 100
- Ask 27.20 x 100
- Day's Range
26.20 - 27.49 - 52 Week Range
4.82 - 27.66 - Volume
1,233,614 - Avg. Volume
1,170,046 - Market Cap (intraday)
2.591B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-2.91 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
45.88
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
www.aviditybiosciences.comRecent News: RNA
Performance Overview: RNA
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNA
Valuation Measures
Market Cap
2.49B
Enterprise Value
1.91B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
199.03
Price/Book (mrq)
4.98
Enterprise Value/Revenue
199.42
Enterprise Value/EBITDA
-8.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.24%
Return on Equity (ttm)
-39.34%
Revenue (ttm)
9.56M
Net Income Avi to Common (ttm)
-212.22M
Diluted EPS (ttm)
-2.91
Balance Sheet and Cash Flow
Total Cash (mrq)
595.35M
Total Debt/Equity (mrq)
1.97%
Levered Free Cash Flow (ttm)
-86.66M
Research Analysis: RNA
Company Insights: RNA
RNA does not have Company Insights